[REQ_ERR: 404] [KTrafficClient] Something is wrong. Enable debug mode to see the reason.

Destiny-breast04 results

See How HER2 Expression Is Reported With Varying Degrees. AdLearn Why Most Breast Cancers Exhibit Varied Levels Not Defined As HER2 Positive. 5. Based on DESTINY-Breast04 results which showed Daiichi Sankyo and AstraZeneca's ENHERTU reduced risk of disease progression or death by 50%. 8. These results mean  . Jun 25, “This new standard of care can improve survival for about 50% of all patients diagnosed with metastatic breast cancer today. Among the patients who had hormone receptor-positive disease, the median progression-free survival was months, while overall survival was months. In the DESTINY-Breast04 trial, the results of which were published in The NEJM last month, patients with HER2-low metastatic breast cancer who had received one or two lines of chemotherapy previously were given trastuzumab deruxtecan. "The implications of the results of the DESTINY-Breast04 trial by Modi et al in this issue of the Journal are difficult to overstate," Hurvitz wrote in her commentary. Among the physician's choice group, which received chemo, the median progression-free survival was months, and overall survival months. “The implications of the results of the DESTINY-Breast04 trial by Modi et al in this issue of the Journal are difficult to overstate,” Hurvitz wrote in her commentary. Among the physician’s choice group, which received chemo, the median progression-free survival was months, and overall survival months. Overall Survival in DESTINY-Breast04 Trial in Patients with First HER2 low metastatic breast cancer phase 3 results for Daiichi Sankyo. 2.

  • Feb 21, DESTINY-Breast04 is the first ever Phase III trial of a HER2-directed therapy in patients with HER2-low metastatic breast cancer to show  .
    • Based on the results of the DESTINY-Breast04 trial, T-DXd was granted Breakthrough Therapy Designation in the United States for the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH negative) breast cancer who Received one systemic therapy in the metastatic phase or relapsed during or within six months of completion of adjuvant chemotherapy. 3, h In some instances, percentages do not add up to % due to rounding. In DESTINY-Breast04, 58% of patients were IHC 1+ and 42% were IHC 2+/ISH−1, g Patients with HR-negative mBC were not included in the primary efficacy analysis. Jun 06,  · Within DESTINY-Breast04, the antibody-drug conjugate (ADC) trastuzumab deruxtecan (T-DXd) successfully prolonged both progression-free survival (PFS) and overall . (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Results of DESTINY-Breast04, a randomized, phase 3 study. in this issue of the Journal are difficult to overstate. . Jul 7, The implications of the results of the DESTINY-Breast04 trial reported by Modi et al. “The strong efficacy of T-DXd in this HER2-low patient population supports the need to now reclassify HER2-low as a new therapeutically targetable category of metastatic breast cancer,” Dr. Modi said. In addition to providing a new treatment option for patients with HER2-low disease, the DESTINY-Breast04 findings justify a shift in the way pathology laboratories report HER2 results. Within DESTINY-Breast04, the antibody-drug conjugate (ADC) trastuzumab deruxtecan (T-DXd) successfully prolonged both progression-free survival (PFS) and overall survival (OS) among patients categorized as having HER2-low unresectable and/or metastatic breast cancer, as compared with physicians' choice of standard single-agent chemotherapy. 1 in this . Jul 07,  · DESTINY-Changing Results for Advanced Breast Cancer, Sara A. Hurvitz, M.D. The implications of the results of the DESTINY-Breast04 trial reported by Modi et al. The. 6. The DESTINY-Breast04 trial was presented at ASCO in the plenary session and simultaneously published in the New England Journal of Medicine. Breast04 trial reported by Modi et al.1 in this issue of  . Jul 7, Hurvitz, M.D.. The implications of the results of the DESTINY-. g Patients with HR-negative mBC were not included in the primary efficacy analysis. 3. h In some instances, percentages do not add up to % due to rounding. In the overall study population (N=), 10% of patients had received 1 prior line of systemic therapy in the metastatic setting, 27% had received 2 prior lines, and 62% had received ≥3 prior lines. 3. In DESTINY-Breast04, 58% of patients were IHC 1+ and 42% were IHC 2+/ISH−1. In , more than 2 million cases of breast cancer were diagnosed worldwide, resulting in nearly , deaths. DESTINY-Breast04 Latest Test Results. HER2 is a tyrosine kinase receptor growth-promoting protein expressed on the surface of. Breast cancer is the most common cancer and one of the leading causes of cancer-related deaths worldwide. Centering discussion on the TROPICS and DESTINY-Breast04 trials, panelists consider the advent of antibody drug conjugates in. 8. 8. Aug 1, DESTINY-Breast04, a phase 3, open-label pivotal trial, randomly assigned patients with unresectable or metastatic HER2-low breast cancer to  . Immediately practice-changing, these data show that. The implications of the results of the DESTINY-Breast04 trial reported by Modi et al. 1 in this issue of the Journal are difficult to overstate. A key consideration in the DESTINY-Breast04 trial was the use of conventional HER2 IHC testing (and HER2 ISH testing when applicable) to identify cancers with HER2-low status. 5. Based on results from the phase 3 DESTINY-Breast04 trial, the FDA has approved fam-trastuzumab deruxtecan-nxki as an intravenous infusion. 8. Jun 14, Erika Hamilton, MD, Sarah Cannon Research Institute, Nashville, TN, speaks on the practice-changing findings from DESTINY-Breast04  . The antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) demonstrated a statistically significant and clinically meaningful progression-free and overall survival benefit versus standard-of-care monotherapy in patients with HER2-low metastatic breast cancer, regardless of hormone receptor status, according to Shanu Modi, MD, of the Memorial Sloan Kettering Cancer Center, New York, and colleagues. ASCO DESTINY-Breast04 Reports Benefit of T-DXd in HER2-Low Metastatic Breast Cancer. 1 in this issue of the Journal are. DESTINY-Changing Results for Advanced Breast Cancer, Sara A. Hurvitz, M.D. The implications of the results of the DESTINY-Breast04 trial reported by Modi et al. (HER2)-Low Breast Cancer. Study description: A phase 3, multicenter. -Breast [Fam-] Trastuzumab Deruxtecan in Human Epidermal Growth Factor Receptor 2. The  . Jun 21, The DESTINY-Breast04 trial was presented at ASCO in the plenary session and simultaneously published in the New England Journal of Medicine.
  • DESTINY-Breast04 is an open-label, multicenter phase 3 study designed to assess the. "Similar TDD results were observed among the all-patient cohort in PRO measures of interest," Ueno noted.
    • The primary results of the multicenter phase III DESTINY-Breast04 trial, which were presented during the American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract LBA3), also seemed to support a "generally manageable" safety profile for this HER2-directed therapy, already approved in HER2-high metastatic breast cancer. vs investigator's choice in HER2-low breast cancer (DESTINY-Breast04) Results from the pivotal, phase 2 study of subjects with. 2. Feb 21, Overall Survival in DESTINY-Breast04 Trial in Patients with First HER2 low metastatic breast cancer phase 3 results for Daiichi Sankyo  . A key consideration in the DESTINY-Breast04 trial was the use of conventional HER2 IHC testing (and HER2 ISH testing when applicable) to identify cancers with HER2-low status. In both arms, compliance for questionnaires was >92% at baseline and >80% for cycles Baseline GHS score was for T-DXd and. DESTINY-Breast04 (NCT) showed improvement in progression-free and overall survival of T-DXd vs TPC in pts with HER2-low MBC regardless of hormone receptor status, with no new safety signals. Results. 7. Dr Judy King (Royal Free Hospital, London, UK) joined touchONCOLOGY to discuss the DESTINY-Breast04 trial results and major highlights in. 7. DESTINY-Breast04 is an open-label, multicenter phase 3 study designed to assess the survival benefit of trastuzumab deruxtecan in patients with pretreated, endocrine refractory, HER2-low disease. Detailed positive results from the pivotal DESTINY-Breast04 Phase III trial showed that Enhertu (trastuzumab deruxtecan) demonstrated superior and clinically meaningful progression-free survival (PFS) and overall survival (OS) in previously treated patients with HER2-low (immunohistochemistry (IHC) 1+ or IHC 2+/in-situ hybridisation (ISH)-negati.